Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study. (Q38365903)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

10

Shunji Takahashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Kenji Nakano

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Lina Inagaki

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Junichi Tomomatsu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Tabu Gokita

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Keisuke Ae

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Taisuke Tanizawa

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Takashi Shimoji

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Seiichi Matsumoto

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

26 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

Japanese Journal of Clinical Oncology

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

449-455

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25724217%20AND%20SRC:MED&resulttype=core&format=json

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

International expert opinion on patient-tailored management of soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

Pazopanib in sarcomas: expanding the PALETTE

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022

Postoperative Nomogram for 12-Year Sarcoma-Specific Death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYV022